Quoin shareholders approve charter amendments and executive compensation; board grants options

Quoin Pharmaceuticals, Ltd.

Shareholders approved amendments to Articles reducing quorum to 33 1/3% (25% for foreign private issuers) and aligning special meeting provisions.
CEO Myers: 2024 base $662,475, FY23 bonus $301,125, option for 536,603 ADSs at $0.78.
COO Carter: 2024 base $529,980, FY23 bonus $240,900, option for 536,609 ADSs at $0.78.
CFO Dunn: 2024 base $433,620, FY23 bonus $197,100, option for 338,994 ADSs at $0.78; non-employee directors each received option for 57,014 ADSs at $0.78.

item 3.03 item 5.02 item 5.07 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.